Currently, BPC-157 is not authorized for human use as it lacks approval for any indication
The cells were cultured in DMEM (Gibco, Gaithersburg, USA) supplemented with 10% fetal bovine serum (Gibco, Gaithersburg, USA), 100 U/mL penicillin, and 100 g/mL streptomycin

International Regulatory Landscape Healthcare Provider Considerations Healthcare providers who prescribe or recommend BPC-157 face potential: Disciplinary action from state medical boards Medical license implications (sanctions, restrictions, suspension) Malpractice liability (insurance often excludes experimental treatments) Federal regulatory enforcement Research and Access Legitimate research pathways: Investigational New Drug (IND) application required for human research Institutional Review Board (IRB) approval required GMP standards required for research-grade materials Current access: Research peptide suppliers (variable quality) Some compounding pharmacies (legal status varies) Clinical trials (limited availability) Why This Regulatory Status Exists BPC-157's prohibition stems from: Limited clinical data Only small pilot studies published (~28 human subjects total)
PloS One 11 (10), e0164021
Dual-Action Compound: A precise scientific blend of BPC-157 and TB-500 for comparative research
If cells are protected from oxidative stress, cellular inflammation is also mitigated